Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NDAC meetings rescheduled

This article was originally published in The Tan Sheet

Executive Summary

Nonprescription Drugs Advisory Committee tentative meeting dates have been rescheduled for June 12-13 and Sept. 16-17. Dietary Supplements Subcommittee tentative meeting dates still slated for March 27-28 and Sept. 22-23, as reported in 1"The Tan Sheet" Dec. 23, 2002, In Brief...

You may also be interested in...



FDA supplement subcommittee

Meeting scheduled for March 25 will evaluate "recognized scientific principles that would facilitate reaching a conclusion as to whether a particular substance is a 'metabolite' of another substance that is a 'dietary ingredient' defined in the [FD&C Act] and, therefore, is itself a dietary ingredient," according to March 5 Federal Register notice. FDA says the act currently "is ambiguous...as to what substances are, or are not, metabolites of other substances," which makes it "often difficult to determine whether a particular substance...can be marketed as [a] dietary supplement." Meeting will be held at Holiday Inn, 10,000 Baltimore Ave., College Park, Md. Dietary Supplement Subcommittee of the Food Advisory Committee will not meet March 27-28, as reported in 1"The Tan Sheet" Feb. 10, 2003, In Brief...

FDA advisory committees

Nonprescription Drugs Advisory Committee slated to meet March 6-7, June 13-14 and Sept. 16-17, according to 1tentative 2003 advisory committee schedule published in Dec. 19 Federal Register. NDAC considered Rx-to-OTC switch applications for Schering-Plough's Claritin (loratadine) and AstraZeneca/Procter & Gamble's Prilosec (omeprazole), and discussed labeling and marketing for acetaminophen, aspirin and NSAIDs in 2002. CFSAN's Dietary Supplements Subcommittee of the Food Advisory Committee is slated to meet March 27-28 and Sept. 22-23, while the parent committee is scheduled to convene Feb. 24-26 and Aug. 18-20...

Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel